When should a beta‑blocker be held in a pregnant patient at 27 weeks gestation?

When to Hold Beta-Blockers in Pregnancy at 27 Weeks

Beta-blockers should generally NOT be held based on heart rate alone in a pregnant patient at 27 weeks gestation, as they are considered safe and recommended for managing hypertension and cardiac conditions during pregnancy. The decision to hold should be based on clinical signs of hemodynamic compromise, not arbitrary heart rate cutoffs.

Key Clinical Framework

Continue Beta-Blockers When:

• Blood pressure remains elevated (≥140/90 mmHg in high-risk patients or ≥150/95 mmHg in others) 1
• Patient is hemodynamically stable (adequate perfusion, no dizziness/syncope)
• No signs of maternal or fetal distress
• The indication for beta-blocker therapy persists (hypertension, arrhythmia, cardiomyopathy)

Consider Holding Beta-Blockers When:

• Symptomatic hypotension with dizziness, syncope, or altered mental status
• Severe bradycardia (<50 bpm) with hemodynamic compromise
• Signs of inadequate end-organ perfusion
• Acute decompensated heart failure requiring alternative management
• Fetal distress potentially related to uteroplacental hypoperfusion

Evidence-Based Rationale

The ESC guidelines explicitly recommend labetalol and metoprolol as safe and effective beta-blockers during pregnancy 1. These medications are used throughout pregnancy, including the second and third trimesters where your patient currently is at 27 weeks.

Important distinction: Unlike ACE inhibitors, ARBs, and direct renin inhibitors which are strictly contraindicated, beta-blockers are recommended to be continued during pregnancy for appropriate indications 1.

Specific Beta-Blocker Considerations:

Preferred agents 1:

• Labetalol (α/β-blocker) - can be given IV for severe hypertension
• Metoprolol - specifically recommended
• These have the most safety data in pregnancy

Caution with atenolol: Some guidelines express concern about atenolol in early pregnancy due to potential fetal growth restriction 2, 3, though this is more relevant to first-trimester exposure.

Monitoring Parameters (Not Holding Parameters)

Rather than holding based on heart rate, focus on:

1. Blood pressure control: Target <140/90 mmHg in high-risk patients 1

2. Maternal symptoms: Perfusion adequacy, dizziness, fatigue beyond normal pregnancy

3. Fetal growth monitoring: Beta-blockers, particularly at high doses, are associated with small-for-gestational-age infants 4, 3

   • High-dose beta-blockers carry 5-fold increased risk of SGA
   • Low-dose carries 2-fold risk
   • This warrants close fetal monitoring but not necessarily discontinuation

4. Uteroplacental perfusion: The concern about "lower BP may impair uteroplacental perfusion" 1 is about excessive BP lowering, not about continuing appropriate therapy

Common Pitfalls to Avoid

Pitfall #1: Holding beta-blockers for asymptomatic bradycardia or "low" heart rate

• Pregnant women normally have increased heart rate, but beta-blockers are still safe
• Hold only for symptomatic bradycardia with hemodynamic compromise

Pitfall #2: Discontinuing effective therapy due to fetal growth concerns

• While dose-dependent SGA risk exists 4, this requires monitoring and possible dose adjustment, not automatic discontinuation
• The maternal indication (hypertension, arrhythmia, cardiomyopathy) often outweighs fetal risks when properly monitored

Pitfall #3: Confusing beta-blocker safety with contraindicated medications

• Beta-blockers are NOT in the same category as ACE inhibitors/ARBs which must be stopped 1

Practical Algorithm

At 27 weeks gestation, hold beta-blocker if:

1. Symptomatic hypotension (SBP <90 mmHg with symptoms) → Hold dose, assess volume status
2. Symptomatic bradycardia (HR <50 with dizziness/syncope) → Hold dose, obtain ECG
3. Acute maternal decompensation requiring ICU-level care → Reassess all medications

Otherwise continue beta-blocker and:

• Monitor BP regularly (target <140/90 or <150/95 depending on risk factors) 1
• Perform serial fetal growth ultrasounds given SGA risk 4
• Consider dose adjustment rather than discontinuation if concerns arise
• Maintain therapy through delivery and postpartum period 5

The Canadian guidelines emphasize that beta-blockers "should be continued" in pregnant women with cardiomyopathy and heart disease 5, reinforcing that continuation rather than holding is the default approach.